Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production

References

• Liang C-W, Yang H-C, Islam MM, et al. Predicting hepatocellular carcinoma with minimal features from electronic health records: development of a deep learning model. JMIR Cancer. 2021;7(4):e19812. doi:10.2196/19812.
   PubMed Web of Science ®Google Scholar
• El-Kassas M, Elbadry M. Hepatocellular carcinoma in Africa: challenges and opportunities. Front Med. 2022;9:899420. doi:10.3389/fmed.2022.899420.
   Web of Science ®Google Scholar
• Quintavalle C, Meyer-Schaller N, Roessler S, et al. miR-579-3p controls hepatocellular carcinoma formation by regulating the phosphoinositide 3-kinase-protein kinase B pathway in chronically inflamed liver. Hepatol Commun. 2022;6(6):1467–1481. doi:10.1002/hep4.1894.
   PubMed Web of Science ®Google Scholar
• Singh A, Raza A. Recent advances in the chemistry and therapeutic evaluation of naturally occurring and synthetic withanolides. Molecules. 2022;27(3):886.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhu L, Gao S, et al. Withanolides isolated from nicandra physaloides protect liver cells against oxidative stress-induced damage. J Funct Foods. 2018;40:93–101. doi:10.1016/j.jff.2017.10.043.
   Web of Science ®Google Scholar
• Palliyaguru DL, Chartoumpekis DV, Wakabayashi N, et al. Withaferin a induces Nrf2-dependent protection against liver injury: role of Keap1-independent mechanisms. Free Radic Biol Med. 2016;101:116–128. doi:10.1016/j.freeradbiomed.2016.10.003.
   PubMed Web of Science ®Google Scholar
• Gu J, et al. Withaferin a exerts preventive effect on liver fibrosis through oxidative stress inhibition in a sirtuin 3-Dependent manner. Oxid Med Cell Longevity. 2020;2020:2452848.
   PubMed Web of Science ®Google Scholar
• Oyewusi HA, Wu Y-S, Safi SZ, et al. Molecular dynamics simulations reveal the inhibitory mechanism of withanolide a against α-glucosidase and α-amylase. J Biomol Struct Dyn. 2023;41(13):6203–6218. doi:10.1080/07391102.2022.2104375.
   PubMed Web of Science ®Google Scholar
• Mohan R, Hammers HJ, Bargagna-Mohan P, et al. Withaferin a is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115–122. doi:10.1007/s10456-004-1026-3.
   PubMedGoogle Scholar
• Wang H-C, Tsai Y-L, Wu Y-C, et al. Withanolides-induced breast cancer cell death is correlated with their ability to inhibit heat protein 90. PLoS One. 2012;7(5):e37764. doi:10.1371/journal.pone.0037764.
   PubMed Web of Science ®Google Scholar
• Yin H, et al. miR-9-5p inhibits skeletal muscle satellite cell proliferation and differentiation by targeting IGF2BP3 through the IGF2-PI3K/akt signaling pathway. Int J Mol Sci. 2020;21(5):1655.
   Web of Science ®Google Scholar
• Yang Z, Wang T, Wu D, et al. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exp Clin Cancer Res. 2020;39(1):203. doi:10.1186/s13046-020-01714-8.
   PubMed Web of Science ®Google Scholar
• Yan A, et al. IGF2BP3 worsens lung cancer through modifying long non-coding RNA CERS6-AS1/microRNA-1202 axis. Curr Med Chem. 2023;30(7):878–891.
   PubMed Web of Science ®Google Scholar
• Xu W, Sheng Y, Guo Y, et al. Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. J Cell Physiol. 2019;234(10):18466–18479. doi:10.1002/jcp.28483.
   PubMed Web of Science ®Google Scholar
• Lian Q, Wang S, Zhang G, et al. HCCDB: a database of hepatocellular carcinoma expression atlas. Genomics Proteomics Bioinf. 2018;16(4):269–275. doi:10.1016/j.gpb.2018.07.003.
   PubMed Web of Science ®Google Scholar
• Jiang G, Huang C, Li J, et al. Role of STAT3 and FOXO1 in the divergent therapeutic responses of non-metastatic and metastatic bladder cancer cells to miR-145. Mol Cancer Ther. 2017;16(5):924–935. doi:10.1158/1535-7163.MCT-16-0631.
   PubMed Web of Science ®Google Scholar
• Wu Q, et al. Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production. Cell Death Dis. 2022;13(4):341.
   PubMed Web of Science ®Google Scholar
• Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64. doi:10.1016/j.semcdb.2017.05.023.
   PubMed Web of Science ®Google Scholar
• Dou C, et al. SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production. J Exp Clin Cancer Res. 2019;38(1):70.
   PubMedGoogle Scholar
• Wang Z, et al. Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma. Cell Proliferation. 2021;54(10):e13117.
   PubMed Web of Science ®Google Scholar
• Zhu L-R, Ni W-J, Cai M, et al. Advances in RNA epigenetic modifications in hepatocellular carcinoma and potential targeted intervention strategies. Front Cell Dev Biol. 2021;9:777007. doi:10.3389/fcell.2021.777007.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang Q, Peng S, et al. The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells. Onco Targets Ther. 2019;12:5359–5373. doi:10.2147/OTT.S212465.
   PubMed Web of Science ®Google Scholar
• Tang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduction Targeted Ther. 2020;5(1):87.
   PubMed Web of Science ®Google Scholar
• Buyel JF. Plants as sources of natural and recombinant anti-cancer agents. Biotechnol Adv. 2018;36(2):506–520. doi:10.1016/j.biotechadv.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Khan H, Saeedi M, Nabavi SM, et al. Glycosides from medicinal plants as potential anticancer agents: emerging trends towards future drugs. Curr Med Chem. 2019;26(13):2389–2406. doi:10.2174/0929867325666180403145137.
   PubMed Web of Science ®Google Scholar
• Khorsandi K, Kianmehr Z, Hosseinmardi Z, et al. Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis. Cancer Cell Int. 2020;20(1):18. doi:10.1186/s12935-020-1100-y.
   PubMed Web of Science ®Google Scholar
• Hussin F, Eshkoor SA, Rahmat A, et al. The Centella asiatica juice effects on DNA damage, apoptosis and gene expression in hepatocellular carcinoma (HCC). BMC Complement Altern Med. 2014;14(1):32. doi:10.1186/1472-6882-14-32.
   PubMedGoogle Scholar
• Wu T, Dong X, Yu D, et al. Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway. Onco Targets Ther. 2018;11:8633–8642. doi:10.2147/OTT.S186186.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang G, Yao F, et al. Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One. 2012;7(5):e37865. doi:10.1371/journal.pone.0037865.
   PubMed Web of Science ®Google Scholar
• Fong MY, Jin S, Rane M, et al. Withaferin a synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One. 2012;7(7):e42265. doi:10.1371/journal.pone.0042265.
   PubMed Web of Science ®Google Scholar
• Xia S, Miao Y, Liu S. Withaferin a induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells. Biochem Biophys Res Commun. 2018;503(4):2363–2369. doi:10.1016/j.bbrc.2018.06.162.
   PubMed Web of Science ®Google Scholar
• Ghosh K, De S, Das S, et al. Withaferin a induces ROS-Mediated paraptosis in human breast cancer Cell-Lines MCF-7 and MDA-MB-231. PLoS One. 2016;11(12):e0168488. doi:10.1371/journal.pone.0168488.
   PubMed Web of Science ®Google Scholar
• Klotz L-O, Sánchez-Ramos C, Prieto-Arroyo I, et al. Redox regulation of FoxO transcription factors. Redox Biol. 2015;6:51–72. doi:10.1016/j.redox.2015.06.019.
   PubMed Web of Science ®Google Scholar
• Prasad SB, Yadav SS, Das M, et al. Down regulation of FOXO1 promotes cell proliferation in cervical cancer. J Cancer. 2014;5(8):655–662. doi:10.7150/jca.6554.
   PubMed Web of Science ®Google Scholar
• Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res. 2011;71(9):3257–3267. doi:10.1158/0008-5472.CAN-10-2603.
   PubMed Web of Science ®Google Scholar
• Goto T, Takano M, Albergaria A, et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. p. Oncogene. 2008;27(1):9–19. doi:10.1038/sj.onc.1210626.
   PubMed Web of Science ®Google Scholar
• Zheng M, Cao M-X, Luo X-J, et al. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells. J Cell Mol Med. 2019;23(10):6942–6954. doi:10.1111/jcmm.14579.
   PubMed Web of Science ®Google Scholar